Vaccine Adjuvants Market Worth $0.96 Billion By 2029 Marketsandmarkets

(MENAFN- GetNews)


"North America dominated the market due to its robust healthcare infrastructure, high R&D investment, and strong focus on immunization programs. Furthermore, the region's dominance is further fueled by government-supported vaccine initiatives, high disease awareness, and strategic investments in pandemic preparedness."Browse 490 market data Tables and 50 Figures spread through 388 Pages and in-depth TOC on "Vaccine Adjuvants Market by Product (Emulsions, Pathogen, Saponin, Particulate), ROA (Subcutaneous, Intramuscular), Disease Type (Infectious, Cancer), Vaccine (Human, Veterinary (Companion, Livestock)), Type (Organic, Inorganic) - Global Forecast to 2029

The vaccine adjuvants industry is poised for remarkable growth in the near future, as the global demand for effective vaccines continues to surge. With ongoing advancements in vaccine technology and an increasing emphasis on vaccine development for emerging infectious diseases, the adjuvant market is set to play a pivotal role in enhancing vaccine efficacy and reducing production costs. Innovations in adjuvant formulations, such as the development of more potent and targeted adjuvants, will likely contribute to the creation of safer and more effective vaccines. Additionally, as governments and organizations worldwide prioritize pandemic preparedness, the vaccine adjuvants sector is expected to witness significant investments, fostering research and development, and driving substantial market expansion. This dynamic landscape holds the promise of revolutionizing vaccine development, ultimately leading to improved public health outcomes on a global scale.

Vaccine Adjuvants Market in terms of revenue was estimated to be worth $0.8 billion in 2023 and is poised to reach $1.2 billion by 2028, growing at a CAGR of 6.9 % from 2023 to 2028 according to a new report by MarketsandMarkets. The global vaccine adjuvants market is expected to grow at a CAGR of 6.9% during the forecast period. The major factors driving the growth of the market are collaborations & partnerships among market players for vaccine adjuvants development, increasing focus on immunization programs and rise in number of vaccine approvals in last 2-3 years.

Download an Illustrative overview:

Browse in-depth TOC on "Vaccine Adjuvants Market" 200 - Tables 45 - Figures 230 - Pages

Vaccine Adjuvants Market Scope:

Report Coverage	Details
Market Revenue in 2023	$0.8 billion
Estimated Value by 2028	$1.2 billion
Growth Rate	Poised to grow at a CAGR of 6.9%
Market Size Available for	2021-2028
Forecast Period	2023–2028
Forecast Units	Value (USD Billion)
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Segments Covered	By Product, By Route of Administration, By Disease Type, By Application, By Type
Geographies Covered	North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa
Report Highlights	Updated financial information / product portfolio of players
Key Market Opportunities	Rising funding for vaccines and infectious disease research activities
Key Market Drivers	Rising prevalence of infectious diseases

The adjuvant emulsions segment is expected to have the dominant share of the vaccine adjuvants market in 2022:

Based on product, the global vaccine adjuvants market is segmented into adjuvant emulsions, pathogen components, saponin-based adjuvants, particulate adjuvants, and other adjuvants. In 2022, the adjuvant emulsions segment accounted for largest share of the vaccine adjuvants market. Increased use of adjuvant emulsions in the vaccine production is serving as driving factor for the growth of the adjuvant emulsions segment during the forecast period.

The infectious disease segment accounted for the largest share of the disease type segment in the vaccine adjuvants market in 2022.

The infectious diseases segment is the fastest growing segment and accounted for the largest share of the market in 2022. The large share of this segment can be attributed to rising demand for novel adjuvanted vaccines for infectious diseases. Rising focus on development of plant-based adjuvants is further likely to have positive impact on the segmental growth.

The Asia Pacific region is the fastest-growing region of the vaccine adjuvants market in 2022.

The Asia Pacific is estimated to be the fastest-growing segment of the market. The growth of the vaccine adjuvants markets on the region is driven by rising emphasis on strategic initiatives such as partnerships, collaborations & expansion and increased adoption of adjuvanted vaccine among the patent population.

Request Sample Pages:

Vaccine Adjuvants Market Dynamics:

Drivers:

Rising prevalence of infectious diseases

Restraints:

Side Effects and High Toxicity of Adjuvants

Opportunities:

Rising funding for vaccines and infectious disease research activities

Challenges:

Concerns regarding animal-sourced vaccine adjuvants and limitations on shark fishing

Key Market Players:

The vaccine adjuvants market is competitive, with a small number of players competing for market shares. Dynavax Technologies (US), GSK plc (UK), Croda International plc (UK), SEPPIC (France), Novavax (US), SPI Pharma (Associated British Foods plc) (UK), Agenus Inc. (US), Phibro Animal Health Corporation (US), Aurorium (Vertellus) (US), Merck KGaA (Germany) are some of the leading players in this market. Most companies in the market focus on organic and inorganic growth strategies, such as product launches, expansions, acquisitions, partnerships, agreements, and collaborations, to increase their product offerings, cater to the unmet needs of customers, increase their profitability, and expand their presence in the global market.

Get 10% Free Customization on this Report:

MENAFN04092025003238003268ID1110019191